Article Text

other Versions

Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial
  1. Ole K Bonderup (obo{at}
  1. Randers Hospital, Denmark
    1. Jesper B Hansen
    1. Aalborg Hospital, Denmark
      1. Peter S Teglbjœrg
      1. Aalborg Hospital, Denmark
        1. Lisbet A Christensen
        1. Århus Hospital, Denmark
          1. Jan F Fallingborg
          1. Aalborg Hospital, Denmark


            Objective: To evaluate the efficacy and safety of long-term budesonide therapy for maintenance of clinical remission in patients with collagenous colitis.

            Design: Randomised, placebo-controlled study with a 24-week, blinded follow-up period without any treatment.

            Setting: Three gastroenterology clinics in Denmark.

            Patients: Forty-two patients with histologically-confirmed collagenous colitis and diarrhoea (>3 stools/day).

            Interventions: Patients in clinical remission after 6 weeks' open-label therapy with oral budesonide (Entocort CIR capsules, 9 mg/day) received 24 weeks' double-blind maintenance therapy with budesonide 6 mg/day or placebo. Thereafter, patients entered the 24-week, blinded follow-up period.

            Main outcome measure: Proportion of patients in clinical remission (≤3 stools/day) at the end of maintenance therapy.

            Findings: A total of 34 patients in remission at week 6 were randomised to budesonide 6 mg/day (n = 17) or placebo (n = 17). After 24 weeks' maintenance treatment, the proportions of patients in clinical remission were 76.5% (13 of 17) with budesonide and 12% (2 of 17) with placebo (p<0.001). At 48 weeks (the end of the follow-up period, without any treatment) these values were 23.5% (4 of 17) and 12% (2 of 17), respectively (p=0.6). The median times to relapse after stopping active treatment (6+24 weeks in the budesonide group; 6 weeks in the placebo group) were 39 and 38 days, respectively. Long-term treatment with budesonide was well tolerated.

            Conclusions: Long-term maintenance therapy with oral budesonide is efficacious and well tolerated for preventing relapse in patients with collagenous colitis. However, the risk of relapse after 24 weeks' maintenance treatment is similar to that observed after 6 weeks' induction therapy.

            Statistics from

            Request Permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

            Linked Articles